At a glance
A combined research record involving GHK-Cu, BPC-157 and a TB-500 preparation.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
This record brings together GHK-Cu, BPC-157 and a TB-500 preparation. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.[1][3][4]
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[2][4][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of GLOW.
A comprehensive adverse-effect profile is not established by the source record. Consult the cited studies for what was measured and what remains uncertain.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 70 mg · 1 source tables
Standard Approach (3 mL = 23.3 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2,330 mcg | 10 units (0.10 mL) |
Frequency: Inject once daily subcutaneously. This schedule maintains a consistent dose throughout the 4-week cycle, delivering approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection. This once-daily regimen aligns with common research protocols for BPC-157 and similar repair peptides[4][5]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily regenerative blend regimen.
- Goal: Support comprehensive tissue healing through synergistic peptide mechanisms—collagen synthesis (GHK-Cu), cell migration and angiogenesis (TB-500), and localized repair with anti-inflammatory effects (BPC-157)[1][3][4].
- Schedule: Daily subcutaneous injections for 4 weeks at a consistent dose, followed by a 2–4 week rest period to assess progress before considering another cycle.
- Dose: 2,330 mcg (2.33 mg) total blend daily, providing approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection.
- Reconstitution: 3.0 mL per 70 mg vial (23.3 mg/mL) for precise unit measurements.
- Storage: Lyophilized vials frozen; reconstituted solutions refrigerated; use within 4 weeks.
Straightforward daily dosing approach for balanced peptide delivery.
- Daily Dose: 2,330 mcg (10 units / 0.10 mL) maintained throughout the 4-week cycle.
- Frequency: Once per day (subcutaneous), at a consistent time preferred.
- Cycle Length: 4 weeks of daily dosing, followed by 2–4 weeks off to evaluate progress and allow receptor resetting.
- Volume: Per-injection volume (~0.1 mL) is well below the 1.0–1.5 mL comfort threshold for subcutaneous administration[7].
- Syringe Recommendation: Use 0.3 mL (30-unit) insulin syringes for greater measurement precision at low volumes.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to minimize foaming.
- Gently swirl or roll the vial until fully dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 4 weeks for optimal potency and safety.
Storage Instructions
Proper storage preserves peptide stability and potency.
- Lyophilized: Store at −20 °C (−4 °F) or below for long-term stability (months to over a year)[6]. If freezer unavailable, refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for shorter durations (weeks). Store in sealed container with desiccant if possible to prevent moisture absorption.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) at all times when not in use[6]. Do not freeze reconstituted solution. Use within 4 weeks (28 days) for optimal potency and safety[6]. Discard any unused solution after this period.
- Allow frozen vials to reach room temperature before opening to prevent condensation.
- Protect reconstituted solution from light (store in amber vial or wrap in foil).
- Inspect solution before each use; discard if discolored, cloudy, or contains precipitate.
Injection Technique
Subcutaneous injection guidance based on clinical best practices[7][7].
- Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry completely.
- Using an insulin syringe (typically 29–31 gauge, 5/16 to 1/2 inch needle), draw up the calculated dose (10 units = 0.1 mL).
- Select a site with adequate subcutaneous tissue (common sites include lower abdomen, thigh, or upper arm).
- Pinch a fold of skin; insert the needle at approximately a 45° angle into the fatty subcutaneous tissue[7]. With short insulin needles, a 90° angle can also be used if injecting into a pinched skin fold.
- Inject slowly over 2–3 seconds; do not aspirate for subcutaneous injections.
- Withdraw needle and apply gentle pressure with a clean cotton swab; do not rub the injection site.
- Rotate sites systematically with each injection, maintaining at least 1–2 inches spacing between sites to prevent tissue irritation.
- Dispose of used syringes and needles immediately in a proper sharps container; never reuse needles.
Materials & quantity planning
Source materials checklist · 70 mg
Plan based on a 4-week daily protocol at standard dosing.
- Peptide Vials (GLOW Blend, 70 mg each):
- 4 weeks (28 days): 1 vial
- Insulin Syringes (U-100, preferably 0.3 mL / 30-unit for precision):
- 4 weeks: 28 syringes (1 per day)
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 4 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- 4 weeks: 56 swabs (2 per day) → recommend 1 × 100-count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 70 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
Vitamins & Hormones (PubMed) — Thymosin β4 Promotes Dermal Healing (2016) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
HSS Journal (PMC) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025) (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Continue exploring
Related topics are not interchangeable compounds or formulations.